» Articles » PMID: 33513851

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease

Overview
Date 2021 Jan 30
PMID 33513851
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: lipoprotein(a) (Lp(a)) is a genetically determined risk factor for coronary artery disease and its complications, although data on the association with other vascular beds and the severity of atherosclerosis is limited. The aim of this study was to evaluate the association of atherosclerosis of various vascular beds with Lp(a), as well as its autoantibodies and generalized inflammatory markers.

Material And Methods: this study included 1288 adult patients with clinical and imaging examination of three vascular beds (coronary, carotid, and lower limb arteries). Patients were categorized according to the number of affected vascular beds (with at least one atherosclerotic stenosis ≥50%): 0 ( = 339), 1 ( = 470), 2 ( = 315), 3 ( = 164). We assessed blood cell count, lipid profile, C-reactive protein, circulating immune complexes, Lp(a), and its autoantibodies.

Results: the number of affected vascular beds was associated with an increasing level of Lp(a) and a lower level of IgM autoantibodies to Lp(a). Hyperlipoproteinemia(a) (Lp(a) ≥ 30 mg/dL) was detected more frequently in patients with atherosclerosis. In logistic regression analysis adjusted for age, sex, hypertension, type 2 diabetes, and smoking, an elevated Lp(a) level was independently associated with stenotic atherosclerosis and lesion severity. There was a positive association of the number of affected vascular beds with C-reactive protein ( = 0.21, < 0.01) and a negative association with circulating immune complexes ( = -0.29, < 0.01). The neutrophil-to-lymphocyte ratio was significantly higher and the lymphocyte-to-monocyte ratio was significantly lower in patients with atherosclerosis compared to the controls ( < 0.01).

Conclusion: Lp(a), C-reactive protein, circulating immune complexes, and neutrophil-to-lymphocyte ratio are associated with the stenotic atherosclerosis of different vascular beds. Lp(a) levels increase and IgM autoantibodies to Lp(a) decrease with the number of affected vascular beds.

Citing Articles

Ultrasound-based prevalence of polyvascular disease and its association with adverse outcome in patients undergoing coronary artery bypass grafting.

Gao J, Cheng Y Sci Prog. 2024; 107(4):368504241297206.

PMID: 39523630 PMC: 11552031. DOI: 10.1177/00368504241297206.


Clinical Diagnostic Significance of Combined Measurement of Lipoprotein(a) and Neck Circumference in Patients with Coronary Heart Disease.

Yang H, Dou J, Guo R, Gao J, Li H, Wang K Int J Gen Med. 2024; 17:5015-5027.

PMID: 39494359 PMC: 11531722. DOI: 10.2147/IJGM.S485570.


Evaluation of Inflammatory Markers in Predicting Coronary Complexity: Insights from the SYNTAX II Score in NSTEMI Patients.

Bilgin M, Akkaya E, Dokuyucu R J Clin Med. 2024; 13(19).

PMID: 39408000 PMC: 11477675. DOI: 10.3390/jcm13195940.


The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis.

Filatova A, Afanasieva O, Arefieva T, Potekhina A, Tyurina A, Klesareva E J Pers Med. 2023; 13(7).

PMID: 37511689 PMC: 10381556. DOI: 10.3390/jpm13071077.


Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis.

Burdeynaya A, Afanasieva O, Ezhov M, Klesareva E, Saidova M, Pokrovsky S Diseases. 2023; 11(1).

PMID: 36975592 PMC: 10047835. DOI: 10.3390/diseases11010043.


References
1.
Gurdasani D, Sjouke B, Tsimikas S, Hovingh G, Luben R, Wainwright N . Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012; 32(12):3058-65. PMC: 4210842. DOI: 10.1161/ATVBAHA.112.255521. View

2.
Varvel S, McConnell J, Tsimikas S . Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arterioscler Thromb Vasc Biol. 2016; 36(11):2239-2245. DOI: 10.1161/ATVBAHA.116.308011. View

3.
Nasr N, Ruidavets J, Farghali A, Guidolin B, Perret B, Larrue V . Lipoprotein (a) and carotid atherosclerosis in young patients with stroke. Stroke. 2011; 42(12):3616-8. DOI: 10.1161/STROKEAHA.111.624684. View

4.
Prasad A, Clopton P, Ayers C, Khera A, de Lemos J, Witztum J . Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. Arterioscler Thromb Vasc Biol. 2017; 37(6):1213-1221. PMC: 5500201. DOI: 10.1161/ATVBAHA.117.309101. View

5.
Bos S, Duvekot M, Touw-Blommesteijn A, Verhoeven A, Mulder M, Watts G . Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. Atherosclerosis. 2015; 242(1):226-9. DOI: 10.1016/j.atherosclerosis.2015.07.024. View